SCHEMBL1754732

SCHEMBL1754732

O=C(CC(C(=O)O)c1ccccc1)c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.71
MEN1 O00255 4/20 0.71
MAPT P10636 3/20 0.67
KDM4E B2RXH2 2/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
L3MBTL1 Q9Y468 2/20 0.67
ALDH1A1 P00352 1/20 0.67
LMNA P02545 1/20 0.67
NPSR1 Q6W5P4 1/20 0.67
TSHR P16473 1/20 0.62
POLB P06746 3/20 0.60
CYP2C19 P33261 3/20 0.54
CYP2C9 P11712 2/20 0.54
PKM P14618 1/20 0.54
PDPK1 O15530 1/20 0.51
ATM Q13315 1/20 0.51
HPGD P15428 2/20 0.50
MAPK1 P28482 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
CYP1A2 P05177 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7821921 0.88 POLB (0.77) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL15075817 0.88 POLB (0.77) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL15075815 0.88 POLB (0.77) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL6201780 0.86 LMNA (0.65) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL12847975 0.85 KMT2A (0.55) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL6408009 0.85 CYP2C9 (0.56) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL435642 0.85 L3MBTL1 (0.63) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL27531722 0.84 KMT2A (0.61) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL15075949 0.84 KMT2A (1.00) KMT2AMEN1MAPTKDM4ESMN1; SMN2
SCHEMBL7828242 0.84 KMT2A (1.00) KMT2AMEN1MAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101260531-A One-room type electrochemical synthesis method for alpha-phenyl-beta-benzoylpropionic acid UNIV EAST CHINA NORMAL (CN) 2008-09-10 CN claimed
EP-0438359-B1 Process for preparing pearl-shaped drugs RHONE POULENC RORER SA (FR) 1994-03-30 EP claimed
CN-1054189-A The method for preparing medicine of round capsuliform RHONE POULENC SANTE (FR) 1991-09-04 CN claimed
EP-2063894-B1 FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS FOR TREATING NEUROINFLAMMATORY DISEASES UNIV NORTHWESTERN (US) 2019-08-28 EP disclosed
EP-1812408-B1 PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS UNIV NORTHWESTERN (US) 2013-10-09 EP disclosed
US-8367672-B2 Pyridazine compounds, compositions and methods UNIVERSITE DE STRASBOURG (FR) 2013-02-05 US disclosed
US-20120245125-A1 PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS UNIVERSITE LOUIS PASTEUR DE STRASBOURG (FR) 2012-09-27 US disclosed
US-8158627-B2 Compositions and treatments using pyridazine compounds and cholinesterase inhibitors NORTHWESTERN UNIVERSITY (US) 2012-04-17 US disclosed
US-20090197885-A1 COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-08-06 US disclosed
US-20080318899-A1 Pyridazine Compounds, Compositions and Methods UNIVERSITE DE STRASBOURG (FR) 2008-12-25 US disclosed
CN-101260531-A One-room type electrochemical synthesis method for alpha-phenyl-beta-benzoylpropionic acid UNIV EAST CHINA NORMAL (CN) 2008-09-10 CN disclosed
WO-2005110987-A1 PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-24 WO disclosed
US-20050256164-A1 NK1 and NK3 antagonists PFIZER INC 2005-11-17 US disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed
EP-0885869-A1 THERAPEUTIC AGENT FOR DIABETES Japan Tobacco Inc. (JP) 1998-12-23 EP disclosed
EP-0010347-B1 NOVEL SUBSTITUTED OMEGA-AROYL(PROPIONYL OR BUTYRYL)-L-PROLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION AMERICAN CYANAMID COMPANY (US) 1983-11-09 EP disclosed
US-4226775-A HYPOTENSIVE AGENTS AMERICAN CYANAMID COMPANY (US) 1980-10-07 US disclosed
EP-0010347-A1 Novel substituted omega-aroyl(propionyl or butyryl)-L-prolines, pharmaceutical compositions containing them and processes for their preparation AMERICAN CYANAMID COMPANY (US) 1980-04-30 EP disclosed
US-4058529-A Polycyclic amino derivatives of pyrrolidone and piperidone CIBA-GEIGY CORPORATION (US) 1977-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256164-A1 NK1 and NK3 antagonists TAC3, TACR1, TACR2 KMT2A 1384/4885MEN1 786/4885MAPT 2851/4885
US-20090197885-A1 COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS ACHE, BCHE, BACE1 KMT2A 1951/4885MEN1 4416/4885MAPT 21/4885
US-20080318899-A1 Pyridazine Compounds, Compositions and Methods APP, PSEN1, PSEN2 KMT2A 3321/4885MEN1 3850/4885MAPT 32/4885
US-20120245125-A1 PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS PSEN1, PSEN2, APP KMT2A 3504/4885MEN1 3706/4885MAPT 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.